The Interleukin 23 Subunit Alpha pipeline drugs market research report outlays comprehensive information on the Interleukin 23 Subunit Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 23 Subunit Alpha pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Gastrointestinal, Musculoskeletal Disorders, and Dermatology which include the indications Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Crohn’s Disease (Regional Enteritis), Ulcerative Colitis, Psoriatic Arthritis, Axial Spondyloarthritis, Unspecified Dermatological Disorders, and Hidradenitis Suppurativa. It also reviews key players involved in Interleukin 23 Subunit Alpha targeted therapeutics development with respective active and dormant or discontinued products.
The Interleukin 23 Subunit Alpha pipeline targets constitutes close to 23 molecules. Out of which, approximately 23 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical, and Discovery stages are 10, 4, 3, 3, and 3 respectively.
Interleukin 23 Subunit Alpha overview
Interleukin 23 subunit alpha (IL-23A) is one of the two subunits of the cytokine Interleukin-23. It is also known as IL-23p19. The IL23A gene encodes this protein in humans. IL-23 is a heterodimeric cytokine composed of IL-23A and an IL-12p40 subunit. The IL23A gene is located on chromosome 5q31-33, while the IL12B gene is located on chromosome 12q13.
For a complete picture of Interleukin 23 Subunit Alpha’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
